Angiotensin Receptor Blockers

Indications for Prior Authorization

Edarbi (azilsartan medoxomil)
  • For diagnosis of Hypertension
    Indicated for the treatment of hypertension to lower blood pressure. Edarbi may be used alone or in combination with other antihypertensive agents.

Edarbyclor (azilsartan and chlorthalidone)
  • For diagnosis of Hypertension
    Indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals.

Tekturna HCT (aliskiren and hydrochlorothiazide)
  • For diagnosis of Hypertension
    Indicated for the treatment of hypertension, to lower blood pressure. Tekturna HCT may be used in patients not adequately controlled with monotherapy. It may also be used as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.

Exforge HCT (amlodipine, valsartan, hydrochlorothiazide)
  • For diagnosis of Hypertension
    Indicated for the treatment of hypertension, to lower blood pressure.

    Limitations of use: Exforge HCT is not indicated for the initial therapy of hypertension.

Criteria

Edarbi, Edarbyclor, Tekturna HCT

For reauthorization request, bypass criteria review and approve through 12/31/2039 For state-mandated plans in Illinois or other states where applicable: Step therapy requirements do NOT apply. Beginning January 1, 2026, step therapy requirements or use of the authorization of alternative covered medications in a manner that effectively creates a step therapy requirement will not be imposed.

Step Therapy

Length of Approval: When approved; no reauthorization required

  • Requested drug is being used for a Food and Drug Administration (FDA)-approved indication
  • AND
  • Trial and failure (of a minimum 30-day supply) or intolerance to one of the following generics:
    • benazepril
    • captopril
    • enalapril
    • fosinopril
    • lisinopril
    • moexipril
    • perindopril
    • quinapril
    • ramipril
    • trandolapril
    • benazepril-HCTZ
    • captopril-HCTZ
    • enalapril-HCTZ
    • fosinopril-HCTZ
    • lisinopril-HCTZ
    • quinapril-HCTZ
    • amlodipine-benazepril
    • trandolapril-verapamil
    • losartan
    • losartan-HCTZ
    • candesartan
    • candesartan-HCTZ
    • irbesartan
    • irbesartan-HCTZ
    • telmisartan
    • telmisartan-HCTZ
    • amlodipine-olmesartan
    • olmesartan
    • olmesartan-HCTZ
    • olmesartan-amlodipine-HCTZ
Exforge HCT

For reauthorization request, bypass criteria review and approve through 12/31/2039 For state-mandated plans in Illinois or other states where applicable: Step therapy requirements do NOT apply. Beginning January 1, 2026, step therapy requirements or use of the authorization of alternative covered medications in a manner that effectively creates a step therapy requirement will not be imposed.

Step Therapy

Length of Approval: When approved; no reauthorization required

  • Requested drug is being used for a Food and Drug Administration (FDA)-approved indication
  • AND
  • Trial and failure (of a minimum 30-day supply) or intolerance to one of the following generics:
    • amlodipine-olmesartan
    • amlodipine-benazepril
    • amlodipine-valsartan
    • telmisartan-amlodipine
    • trandolapril-verapamil
    • benazepril-HCTZ
    • candesartan-HCTZ
    • captopril-HCTZ
    • enalapril-HCTZ
    • fosinopril-HCTZ
    • lisinopril-HCTZ
    • losartan-HCTZ
    • olmesartan-HCTZ
    • quinapril-HCTZ
    • telmisartan-HCTZ
    • olmesartan-amlodipine-HCTZ
P & T Revisions

1970-01-01, 2025-12-18, 2025-07-02, 2025-05-28, 2024-06-05, 2023-10-13, 2023-06-06, 2021-12-01, 2021-06-07, 2020-04-01

  1. Edarbi prescribing information. Azurity Pharmaceuticals. Atlanta, GA. January 2024.
  2. Edarbyclor prescribing information. Azurity Pharmaceuticals. Atlanta, GA. March 2023.
  3. Tekturna HCT prescribing information. Noden Pharma USA, Inc. Boston, MA. May 2023.
  4. Exforge HCT prescribing information. Novartis Pharmaceuticals Corp. East Hanover, New Jersey. May 2023.

  • 2025-12-18: no criteria changes, added IL statute operational note
  • 2025-07-02: 2025 Annual Review. No criteria changes. Removed obsolete GPIs.
  • 2025-05-28: Removing reauthorization requirement as part of extended reauthorization program.
  • 2024-06-05: 2024 Annual Review. Added "of a minimum 30-day supply" to trial and failure criteria. Removed Tekturna as a target from guideline. Background updates.
  • 2023-10-13: GPI cleanup, no change to clinical intent.
  • 2023-06-06: Annual review, no changes
  • 2021-12-01: Program update to include Exforge HCT criteria
  • 2021-06-07: Annual Review
  • 2020-04-01: Reference updates only